Bornholm disease future or investigational therapies

Jump to navigation Jump to search

Bornholm disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Bornholm disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bornholm disease future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bornholm disease future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bornholm disease future or investigational therapies

CDC on Bornholm disease future or investigational therapies

Bornholm disease future or investigational therapies in the news

Blogs on Bornholm disease future or investigational therapies

Directions to Hospitals Treating Bornholm disease

Risk calculators and risk factors for Bornholm disease future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S

Overview

The prevention of Bornholm disease focuses on preventing infections with Coxsackie virus, as it is the most common underlying cause. The Coxsackie virus can  persist for prolonged durations. The Coxsackie virus is an RNA virus that is non-enveloped, positive single stranded and has the ability to form an envelope by taking over host membranes which provides resistance. The relationship between Coxsackie viral infections and chronic disease is also of interest, especially autoimmune conditions. These include chronic myocarditis, diabetes and chronic inflammatory myopathy. Apart from studying the relationship between coxsackie virus and chronic conditions, the effects in utero are also being studied. Neonates may present with fetal myocarditis and neurodevelopmental delays, possibly due to meningitis and encephalitis.

Future or Investigational therapies

To understand prevention, it is important to first understand the properties of the virus. Coxsackie virus is:[1]

  • non-enveloped; which allows it to survive in harsh environments
  • RNA virus
  • positive single stranded
  • ability to form an envelope by taking over host membranes; provides resistance

Currently, studied are being done to understand the relationship between Coxsackie virus and in utero infections. Newborns may present with fetal myocarditis and neurodevelopmental delays, possibly due to meningitis and encephalitis. The risk of spontaneous abortions is also higher, and the mortality rate is around 10%.[2]

As the disease presents in the form of epidemics and affects masses of individuals at once, vaccinations are also being studied. Due to the genetic variability and various disease possibilities, this process remains a challenge.

The relationship between Coxsackie viral infections and chronic disease is also of interest, especially autoimmune conditions. These include chronic myocarditis, diabetes and chronic inflammatory myopathy.[3]

References

  1. Sin J, Mangale V, Thienphrapa W, Gottlieb RA, Feuer R (2015). "Recent progress in understanding coxsackievirus replication, dissemination, and pathogenesis". Virology. 484: 288–304. doi:10.1016/j.virol.2015.06.006. PMC 4567421. PMID 26142496.
  2. Ornoy A, Tenenbaum A (2006). "Pregnancy outcome following infections by coxsackie, echo, measles, mumps, hepatitis, polio and encephalitis viruses". Reprod Toxicol. 21 (4): 446–57. doi:10.1016/j.reprotox.2005.12.007. PMID 16480851.
  3. Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J, Sarvetnick N (1998). "Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry". Nat Med. 4 (7): 781–5. doi:10.1038/nm0798-781. PMID 9662368.

Template:WH Template:WS